Farringdon Capital, Ltd. Nektar Therapeutics Transaction History
Farringdon Capital, Ltd.
- $198 Billion
- Q1 2025
A detailed history of Farringdon Capital, Ltd. transactions in Nektar Therapeutics stock. As of the latest transaction made, Farringdon Capital, Ltd. holds 21,270 shares of NKTR stock, worth $14,463. This represents 0.01% of its overall portfolio holdings.
Number of Shares
21,270Holding current value
$14,463% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding NKTR
# of Institutions
168Shares Held
122MCall Options Held
1.18MPut Options Held
64.6K-
Black Rock Inc. New York, NY15.2MShares$10.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.3MShares$8.37 Million0.0% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT7.79MShares$5.3 Million0.24% of portfolio
-
Acadian Asset Management LLC Boston, MA7.2MShares$4.9 Million0.02% of portfolio
-
Eventide Asset Management, LLC Boston, MA6.65MShares$4.52 Million0.1% of portfolio
About NEKTAR THERAPEUTICS
- Ticker NKTR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 187,404,992
- Market Cap $127M
- Description
- Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...